Asia
Sansure Biotech of Changsha raised $77M in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital.
The company will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products.
Laviana Pharma closed a $15M Series B funding led by Shenzhen Huayi Capital.
Shanghai’s SARI was the lead investor in a $359M acquisition of a 90% interest in Group NMS, a Milan oncology biopharma with CRO operations.
Fosun contributed $50M to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering.
Cellular Biomedicine added $14.5M into its treasury through two private placements, one to key executives and the other to outside investors.
The drugmaker intends to expand development of therapeutic antibodies at the lab.
A look at a few biotechs which should outperform the market in 2018.
The incubator will be located at Merck Serono’s current facilities in Yavne, a town in central Israel.
The company will use the capital to support a China Phase III trial of APL-1202, a repurposed oral inhibitor of MetAP2.
PRESS RELEASES